← Eichor
Study identifier: NCT06361160 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation

Condition: Treatment Resistant Schizophrenia  ·  Sponsor: Centre Hospitalier St Anne

PhaseNA
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Approximately 1% of the general population will be affected by schizophrenia over the course of their lives, with life expectancy being reduced by 20 years on average and quality of life being severely diminished in affected individuals. One third of patients suffering from schizophrenia will evolve towards a resistant form of the disease, amongst which many will suffer from auditory-verbal hallucinations (AVH) that current therapeutic approaches struggle to alleviate. Previous work from our team has demonstrated the possibility of robustly inferring the periods of occurrence of AVH from fMRI data, paving the way for the development of a closed-loop neuromodulation system comprised of an electrode array positioned in Broca's area, which would detect AVH in real time, and effector electrodes which would stimulate the temporo-parietal cortex to interrupt them. The aim of this project is to assess the feasibility of this system. To do so, we will first test the ability of transcranial magnetic stimulation of the "continuous theta burst" (cTBS) type, applied at the time of AVH onset, to reduce their duration and intensity, and assess whether this is associated with therapeutic response to the current gold standard rTMS protocol for AVH reduction through neuroplasticity induction. Demonstrating the feasibility of acute suppression of AVH by cortical neurostimulation is an essential element in the feasibility of a closed-loop reactive neuromodulation system. The research project c…

This description comes directly from the study's public registry record.

Talk to the study team

Philippe Domenech, MD, PhD  ·  (0)1 49 81 22 01  ·  philippe.domenech@ghu-paris.fr

Fabien Vinckier, MD, PhD  ·  (0) 1 45 65 84 52  ·  f.vinckier@ghu-paris.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Groupe Hospitalo-Universitaire Paris Psychiatrie & NeurosciencesParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06361160